OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal

• The FDA had refused to approve the drug in December, but Outlook appealed the decision. 
• The resubmission follows the agency's conclusion that no additional trials for Lytenava are required, as substantial evidence of effectiveness has already been established.
• If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab.

Shares of Outlook Therapeutics, Inc. (OTLK) jumped 21% on Monday after the company announced that it has resubmitted the application to the U.S. Food and Drug Administration seeking approval for its drug Lytenava in the treatment of neovascular age-related macular degeneration (nAMD).

The FDA had refused to approve the drug in December, but Outlook appealed the decision, and the FDA Office of New Drugs subsequently concluded that no additional trials are required as substantial evidence of effectiveness has already been established. The agency instead directed the review division to focus on final product labeling, the company added.

A decision on the resubmitted application is expected within 60 days of the FDA’s receipt of it, the company said. Neovascular age-related macular degeneration (nAMD), commonly known as wet AMD, is a severe, progressive eye condition where abnormal blood vessels grow uncontrollably under the retina. These fragile vessels leak fluid and blood, causing rapid and often irreversible central vision loss if left untreated.

A Long Regulatory Road

This marks the latest chapter in Outlook Therapeutics’ multi-year effort to secure FDA approval for Lytenava.

The company’s original application was accepted by the FDA in October 2022. In August 2023, the agency issued its first letter refusing approval, citing Chemistry, Manufacturing, and Controls (CMC) deficiencies, observations from pre-approval manufacturing inspections, and insufficient substantial evidence of effectiveness.

Outlook responded by addressing the manufacturing issues and, in early 2025, resubmitted the application. The FDA accepted it in April 2025, but the agency denied it approval again in late 2025, this time focusing on a perceived lack of confirmatory efficacy evidence and recommending additional data.

The company then engaged the FDA through a meeting and pursued a Formal Dispute Resolution (FDR) process. On May 26, Outlook announced that the Office of New Drugs had granted the appeal, clearing the path for the current resubmission.

If approved, Lytenava would become the first and only FDA-approved ophthalmic formulation of bevacizumab, an antibody medication used to treat various solid tumors and specific eye diseases. The product is already approved in the European Union and the United Kingdom.

How Did OTLK Retail Traders React?

On Stocktwits, retail sentiment around OTLK stayed within the “extremely bullish” territory over the past 24 hours, while message volume stayed at “extremely high” levels.

A Stocktwits user expressed optimism that the FDA would approve the drug, provided the agency has already acknowledged that the company's trials are evidence of efficacy.

Another user said that they have reversed their previous bearish take on the stock after the company’s appeal and shift in the FDA’s take on the company’s trials.

OTLK stock has fallen 50% over the past 12 months. 

Read More: WMT Reportedly Caps Employee AI Usage — Stock Down Nearly 2%

For updates and corrections, email newsroom[at]stocktwits[dot]com.